Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s traded shares stood at 388,908 during the last session, with the company’s beta value hitting 0.93. At the close of trading, the stock’s price was $49.55, to imply a decline of -0.32% or -$0.16 in intraday trading. The IOVA share’s 52-week high remains $52.43, putting it -5.81% down since that peak but still an impressive +62.26% since price per share fell to its 52-week low of $18.7. The company has a valuation of $7.27 Billion, with an average of 1.9 Million shares in intraday trading volume over the past 10 days and average of 1.52 Million shares over the past 3 months.
Analysts have given a consensus recommendation of Overweight for Iovance Biotherapeutics, Inc. (IOVA), translating to a mean rating of 1.8. Of 12 analyst(s) looking at the stock, none analyst(s) give IOVA a Sell rating. 2 of those analysts rate the stock as Overweight while 2 advise Hold as 8 recommend it as a Buy. None analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.44.
After registering a -0.32% downside on the day, Iovance Biotherapeutics, Inc. (IOVA) has traded green over the past five days. The stock hit a weekly high of $51.23 this Tuesday, Dec 22, jumping 3.28% in its intraday price action. The 5-day price performance for the stock is 7.09%, and 33.34% over 30 days. With these gigs, the year-to-date price performance is 79.01%. Short interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) saw shorts transact 16.78 Million shares and set a 11.04 days time to cover.
Analysts on Wall Street suggest a consensus price target of $49.73, implying an increase of 0.36% to the stock’s current value. The extremes give us $35 and $60 for target low and target high price respectively. As such, IOVA is trading 21.09% off suggested target high and -29.36% from its likely low.
Iovance Biotherapeutics, Inc. (IOVA) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings fell an estimated -27% for the past 5-year period. While 2020 is set for a -25.1% return in earnings, projections for the next 5 years are at 0% annually.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics, Inc. insiders hold 0.77% of total outstanding shares, with institutional holders owning 99.4% of the shares at 100.17% float percentage. In total, 347 institutions holds shares in the company, led by Vanguard Group, Inc. (The). As of Sep 29 this year, the company held over 11.78 Million shares (or 8.03% of shares), all amounting to roughly $387.75 Million.
The next major institution holding the largest number of shares is Perceptive Advisors Llc with 10.09 Million shares, or about 6.88% of shares outstanding. As of the market price on Sep 29, these shares were worth $332.02 Million.
We also have ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Iovance Biotherapeutics, Inc. (IOVA) shares. Going by data provided on Jul 30, ARK ETF Tr-ARK Innovation ETF holds roughly 3,843,729 shares. This is just over 2.62% of the total shares, with a market valuation of $111.74 Million. Data from the same date shows that the other fund manager holds a little less at 3.72 Million, or 2.54% of the shares, all valued at about $122.54 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.